Mutated EGFR-IN-2 is primarily used in cancer research, particularly in the study of non-small cell lung cancer (NSCLC). It functions as an inhibitor targeting mutated epidermal growth factor receptor (EGFR), which is often overactive in certain cancers. By blocking this receptor, it helps in understanding the mechanisms of tumor growth and resistance to treatment. This compound is valuable in developing targeted therapies that can potentially improve outcomes for patients with EGFR mutations. It is also utilized in preclinical studies to evaluate the efficacy and safety of new cancer drugs.